Healthcare Industry News: Kyphon
News Release - August 6, 2007
Carticept Medical Expands Management Team with Appointment of Chris Fair to Vice President, Sales and Marketing
ALPHARETTA, Ga.--(HSMN NewsFeed)--Carticept Medical, Inc., a developer of innovative products for the treatment of damaged cartilage, today announced the appointment of Christopher T. Fair to the newly created position of vice president, sales and marketing.Prior to joining Carticept, Fair, 37, was vice president, sales at St. Francis Medical Technologies, Inc., a privately held company that developed and marketed novel treatments for degenerative spinal disorders, where he oversaw the successful launch of the X STOP, the first and only FDA-approved interspinous process implant to treat Lumbar Spinal Stenosis. Chris was instrumental in the $725 million acquisition of St. Francis by Kyphon Inc. earlier this year.
From 1995 to 2004, Fair served in a variety of marketing and sales roles at DePuy Spine, the spine division of Johnson & Johnson, most recently as territory General Manager. Chris holds a B.S. in Business Administration from the University of Richmond.
"We are delighted that Chris is joining the management team at Carticept," said Timothy J. Patrick, president and chief executive officer. "Chris' strengths in business development, strategic planning and launching new orthopedic devices will be a valuable asset to Carticept Medical. As we continue to move our products forward, Chris will be a key source of expertise on our senior management team."
About Carticept Medical
Based in Alpharetta, Ga., Carticept Medical, Inc. is a privately held medical device company established in 2005 to develop innovative solutions for patients with painful cartilage compromise. Major investors include Domain Associates and New Enterprise Associates. Additional information is available on the company's web site at www.carticept.com.
Source: Carticept Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
